Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Jun 13 04:00PM ET
6.10
Dollar change
-0.13
Percentage change
-2.09
%
Index- P/E- EPS (ttm)-33.14 Insider Own34.20% Shs Outstand1.92M Perf Week-5.57%
Market Cap11.69M Forward P/E- EPS next Y-19.72 Insider Trans1.55% Shs Float1.26M Perf Month-12.86%
Income-63.35M PEG- EPS next Q-6.32 Inst Own19.08% Short Float1.71% Perf Quarter-26.33%
Sales3.64M P/S3.21 EPS this Y24.73% Inst Trans-3.68% Short Ratio1.10 Perf Half Y-46.59%
Book/sh24.42 P/B0.25 EPS next Y20.61% ROA-55.38% Short Interest0.02M Perf Year-59.80%
Cash/sh20.67 P/C0.30 EPS next 5Y24.06% ROE-83.92% 52W Range5.20 - 15.60 Perf YTD-43.00%
Dividend Est.- P/FCF- EPS past 5Y-13.73% ROIC-91.65% 52W High-60.90% Beta0.92
Dividend TTM- Quick Ratio3.13 Sales past 5Y104.50% Gross Margin52.67% 52W Low17.31% ATR (14)0.65
Dividend Ex-Date- Current Ratio3.13 EPS Y/Y TTM0.40% Oper. Margin-1738.84% RSI (14)44.27 Volatility5.51% 5.45%
Employees52 Debt/Eq0.53 Sales Y/Y TTM-67.87% Profit Margin-1741.26% Recom2.60 Target Price40.00
Option/ShortNo / Yes LT Debt/Eq0.48 EPS Q/Q-1.39% Payout- Rel Volume0.57 Prev Close6.23
Sales Surprise61.36% EPS Surprise18.31% Sales Q/Q-76.83% EarningsMay 12 AMC Avg Volume19.63K Price6.10
SMA20-3.18% SMA50-9.71% SMA200-39.30% Trades Volume11,148 Change-2.09%
Date Action Analyst Rating Change Price Target Change
Jan-06-22Downgrade Morgan Stanley Overweight → Equal-Weight
Mar-02-21Initiated SVB Leerink Outperform $36
Mar-02-21Initiated Stifel Buy $40
Mar-02-21Initiated Morgan Stanley Overweight $45
Mar-02-21Initiated Guggenheim Buy $42
May-12-25 05:25PM
05:10PM
04:28PM
04:05PM
May-10-25 11:55AM
05:50PM Loading…
May-08-25 05:50PM
08:00AM
Apr-30-25 04:05PM
Apr-25-25 01:00PM
Mar-25-25 04:30PM
Mar-24-25 04:37PM
04:20PM
Feb-25-25 04:05PM
Feb-11-25 04:05PM
Nov-12-24 05:35PM
04:27PM Loading…
04:27PM
04:05PM
Nov-07-24 10:00AM
Sep-04-24 04:05PM
Aug-28-24 07:00AM
Aug-13-24 04:05PM
May-24-24 06:13AM
May-15-24 03:00PM
01:34PM
08:05AM
07:29AM
May-14-24 10:54PM
04:05PM
Mar-21-24 10:53PM
04:05PM
07:00AM Loading…
Feb-27-24 07:00AM
Dec-21-23 07:30AM
Dec-05-23 07:00AM
Nov-09-23 04:05PM
Nov-07-23 07:00AM
Oct-24-23 12:30PM
Oct-23-23 10:30AM
Oct-18-23 07:00AM
Oct-17-23 07:00AM
Oct-16-23 07:00AM
Sep-28-23 07:00AM
Sep-12-23 08:05AM
Sep-05-23 04:15PM
Aug-09-23 06:10AM
Aug-07-23 04:10PM
Aug-03-23 07:30AM
Jul-31-23 05:27PM
Jun-13-23 11:22AM
May-30-23 08:00AM
May-25-23 05:05PM
May-11-23 04:05PM
Apr-26-23 10:00AM
Apr-11-23 07:41AM
Mar-30-23 01:16PM
Mar-29-23 04:15PM
04:05PM
Mar-14-23 04:30PM
Feb-28-23 08:00AM
Feb-01-23 08:00AM
Jan-04-23 09:31AM
Dec-14-22 04:43PM
Nov-10-22 04:05PM
Nov-07-22 08:00AM
Nov-02-22 07:20AM
Nov-01-22 10:01AM
08:00AM
Sep-09-22 12:08PM
Aug-31-22 07:30AM
Aug-25-22 12:23PM
12:02PM
Aug-10-22 04:05PM
Jul-22-22 08:44AM
Jun-10-22 07:21AM
May-27-22 08:00AM
May-26-22 06:52AM
May-13-22 08:28AM
May-12-22 04:05PM
May-11-22 07:32AM
Apr-07-22 08:00AM
Mar-30-22 04:05PM
Mar-08-22 04:30PM
Feb-12-22 06:30AM
Feb-02-22 08:00AM
Jan-27-22 01:43PM
Jan-06-22 08:00AM
Dec-17-21 06:14AM
Dec-16-21 08:00AM
Dec-06-21 04:29PM
09:23AM
06:00AM
Dec-02-21 06:00AM
Nov-19-21 08:00AM
Nov-12-21 07:00AM
Nov-09-21 04:05AM
Nov-08-21 08:00AM
Nov-03-21 08:00AM
Oct-01-21 08:00AM
Sep-08-21 07:30AM
Sep-02-21 08:00AM
Aug-27-21 05:55AM
Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. Its pipeline includes BDC-1001, a HER2-targeting Boltbody Immune-Stimulating Antibody Conjugate (ISAC), BDC-3042, a myeloid-modulating antibody, and multiple Boltbody ISAC collaboration programs. The company was founded by Edgar G. Engleman on January 22, 2015 and is headquartered in Redwood City, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Nemec SarahSenior VP, Finance and PAODec 16 '24Buy0.502,5001,24116,633May 05 08:40 PM
Quinn William P.President, CEO and CFODec 16 '24Buy0.502,5001,24141,272May 05 08:35 PM